Bristol Myers cancer drug slows rare tumor progression
Drugmaker's shares rise as analysts say results validate radiopharmaceutical platform
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.businesslive.co.za — the content belongs to Business Day.
